XORTX Announces Acquisition Extension; Shares Rise on Renal Anti-Fibrotic Therapeutic Deal

XORTX Pharmaceuticals (NASDAQ: XORT) extended the closing deadline for its acquisition of a renal anti-fibrotic therapeutic program, signaling continued momentum in its pipeline expansion. The revised timeline, effective February 15, 2026, follows positive preliminary regulatory discussions and aligns with the company's strategy to strengthen its indications in chronic kidney disease. The acquisition, valued at approximately $25 million, is expected to add a late-stage candidate with potential co-development opportunities. The stock closed 12% higher on the news, reflecting market confidence in the deal's strategic value and growth prospects.